EPIM
Evelyn Partners Investment Management Portfolio holdings
AUM
$2.42B
This Quarter Return
-2.87%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$2.2B
AUM Growth
–
Cap. Flow
+$2.2B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
52.29%
Holding
261
New
261
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Microsoft
MSFT
|
+$196M |
| 2 |
Amazon
AMZN
|
+$190M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$157M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$118M |
| 5 |
Visa
V
|
+$110M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 21.97% |
| 2 | Financials | 20.95% |
| 3 | Healthcare | 16.15% |
| 4 | Consumer Discretionary | 14.67% |
| 5 | Communication Services | 11.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Viatris
VTRS
$12.2B
| $14.6K | ﹤0.01% |
+1,588
| New | +$14.6K |
|
227
Sempra
SRE
$51.9B
| $14.3K | ﹤0.01% |
+338
| New | +$14.3K |
|
228
Fortive
FTV
$16.1B
| $13.4K | ﹤0.01% |
+183
| New | +$13.4K |
|
229
Dropbox
DBX
$8.3B
| $13.4K | ﹤0.01% |
+6,245
| New | +$13.4K |
|
230
Petrobras
PBR
$80.1B
| $11.8K | ﹤0.01% |
+14,910
| New | +$11.8K |
|
|
ONC
231
BeOne Medicines Ltd. American Depositary Shares
ONC
$38.4B
| $11.2K | ﹤0.01% |
+165
| New | +$11.2K |
|
232
HCA Healthcare
HCA
$95.6B
| $10.4K | ﹤0.01% |
+30
| New | +$10.4K |
|
233
Arvinas
ARVN
$576M
| $10.3K | ﹤0.01% |
+346
| New | +$10.3K |
|
234
Fair Isaac
FICO
$37B
| $9.22K | ﹤0.01% |
+37
| New | +$9.22K |
|
235
Zimmer Biomet
ZBH
$20.7B
| $9.06K | ﹤0.01% |
+80
| New | +$9.06K |
|
236
Neogen
NEOG
$1.24B
| $8.67K | ﹤0.01% |
+63
| New | +$8.67K |
|
237
AdvanSix
ASIX
$563M
| $8.59K | ﹤0.01% |
+14,897
| New | +$8.59K |
|
238
Kyndryl
KD
$7.66B
| $8.48K | ﹤0.01% |
+274
| New | +$8.48K |
|
239
Synopsys
SNPS
$113B
| $8.15K | ﹤0.01% |
+1,677
| New | +$8.15K |
|
240
TransUnion
TRU
$18.1B
| $8.13K | ﹤0.01% |
+98
| New | +$8.13K |
|
241
T-Mobile US
TMUS
$272B
| $6.67K | ﹤0.01% |
+302
| New | +$6.67K |
|
242
Idexx Laboratories
IDXX
$52.1B
| $5.04K | ﹤0.01% |
+12
| New | +$5.04K |
|
243
Cadiz
CDZI
$302M
| $4.01K | ﹤0.01% |
+934
| New | +$4.01K |
|
244
Mattel
MAT
$5.94B
| $3.89K | ﹤0.01% |
+178
| New | +$3.89K |
|
245
Apellis Pharmaceuticals
APLS
$3.38B
| $3.28K | ﹤0.01% |
+1,377
| New | +$3.28K |
|
246
Chemours
CC
$2.42B
| $2.57K | ﹤0.01% |
+2,463
| New | +$2.57K |
|
247
Takeda Pharmaceutical
TAK
$48.4B
| $2.49K | ﹤0.01% |
+955
| New | +$2.49K |
|
248
Solventum
SOLV
$12.9B
| $2.43K | ﹤0.01% |
+6
| New | +$2.43K |
|
|
GRAL
249
GRAIL, Inc. Common Stock
GRAL
$1.36B
| $2.09K | ﹤0.01% |
+1,665
| New | +$2.09K |
|
250
Embecta
EMBC
$856M
| $1.46K | ﹤0.01% |
+128
| New | +$1.46K |
|